Controlling Quality and Capturing Uncertainty in Advanced Diffusion Weighted MRI
Project Number5R01EB017230-08
Former Number2R01EB017230-05
Contact PI/Project LeaderLANDMAN, BENNETT A.
Awardee OrganizationVANDERBILT UNIVERSITY
Description
Abstract Text
PROJECT SUMMARY
Alzheimer’s Disease and related dementia are a growing public health crisis affecting 5.8 million Americans, yet
there are only four FDA-approved medications for Alzheimer’s Disease, none of which are disease-modifying.
Hence, early detection and diagnosis are key to successful patient management and biomarkers are needed for
evaluating new therapies in clinical trials. White matter changes are increasingly implicated in early Alzheimer’s
Disease progression, and diffusion weighted magnetic resonance imaging (DW-MRI) has been included in many
national-scale studies. Yet, quantitative investigation of DW-MRI data is hindered by a lack of consistency due
to variation in acquisition protocols, sites, and scanners. DW-MRI enables quantification of brain microstructure
and facilitates structural connectivity mapping. Substantial recent progress has been made with calibration and
harmonization to reduce inter-subject variance and improve interpretability of computed measures. Yet, the
fundamental challenge remains that clinical application of DW-MRI (as currently implemented) is
confounded by inter-scanner and inter-site effects.
To improve understanding of structural changes in Alzheimer’s Disease, we will construct and evaluate three
separate analysis strategies to characterize, calibrate, and optimize DW-MRI for single-subject biomarker
development for Alzheimer’s Disease. We will integrate and optimize our strategies using large retrospective
multi-site studies and validate the approaches on two distinct prospective cohorts. Specifically, we aim to:
Aim 1: Optimize data-driven techniques for stability across sessions, scanners/sites, and field strengths
Impact: Harmonized DW-MRI methods will increase sensitivity to Alzheimer’s Disease and its prodromal stages.
Aim 2: Translate innovations in microstructural harmonization to structural connectivity (tractography)
Impact: Harmonizing structural connectivity will improve understanding of white matter in Alzheimer’s Disease.
Aim 3: Advance statistical tools for single-subject inference through normative database construction
Impact: Data-driven resources for uncertainty estimation will enable robust single-single subject inference.
Relevance and Impact on Healthcare: The proposed research will advance understanding of Alzheimer’s
Disease through (1) quantitative harmonization of DW-MRI biomarkers, (2) protocols for harmonization of
retrospective and prospective DW-MRI studies, and (3) new tools for single subject inference targeting older
cohorts. We will organize workshops/challenges to maximize the translational impact on clinical science. The
long-term goal of our research is to (1) provide a well-validated strategy to quantitatively evaluate DW-MRI data
across sites, (2) enhance DW-MRI biomarkers for Alzheimer’s Disease, and (3) advance patient care. Our
research strategy will transform the manner in which DW-MRI data are interpreted and enable single-subject
machine learning to interpret brain properties. The resources, software, and visualization tools will be made
freely available in open source through DIPY to facilitate continued innovation.
Public Health Relevance Statement
PROJECT NARRATIVE
Alzheimer’s Disease is a significant public health concern, and identifying opportunities for early intervention is
critical to developing effective interventional strategies. Diffusion weighted magnetic resonance imaging (DW-
MRI) has shown that subtle changes in cerebral white matter are prognostic for disease progression, but
quantitative interpretation of these measures in existing large studies is confounded by protocol, scanner, and
site effects. This study will translate recent advances in harmonization of DW-MRI to improve specificity of white
matter microarchitecture metrics (aim 1), translate connectivity analyses (aim 2) for existing large Alzheimer’s
Disease neuroimaging studies, and enable robust single subject inference for abnormality detection and
prognosis (aim 3).
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
965717143
UEI
GTNBNWXJ12D5
004413456
DWH7MSXKA2A8
Project Start Date
20-September-2015
Project End Date
30-June-2025
Budget Start Date
01-July-2024
Budget End Date
30-June-2025
Project Funding Information for 2024
Total Funding
$618,643
Direct Costs
$520,408
Indirect Costs
$98,235
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Biomedical Imaging and Bioengineering
$618,643
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01EB017230-08
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01EB017230-08
Patents
No Patents information available for 5R01EB017230-08
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01EB017230-08
Clinical Studies
No Clinical Studies information available for 5R01EB017230-08
News and More
Related News Releases
No news release information available for 5R01EB017230-08
History
No Historical information available for 5R01EB017230-08
Similar Projects
No Similar Projects information available for 5R01EB017230-08